Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

Impact · against what's priced in

The news regarding Marvel Biosciences (MRVL) is not material for Marvell Technology, as the ticker in the reconstruction refers to a semiconductor company, while the article describes a biotech firm. For the biotech entity, selecting a clinical site is a positive step toward first-in-human testing, though it remains early-stage.

MRVL+0.00: Doesn't touch the price's assumptions
In context: The priced-in reconstruction is for Marvell Technology, a semiconductor firm focused on data centers and AI silicon, whereas this article concerns Marvel Biosciences, a biotech company developing ASD therapeutics.

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

What matters in this story

How each ticker is affected

Gilead's pill succeeds in mid-stage bowel disease trial

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

What matters in this story

How each ticker is affected

Gilead's pill succeeds in mid-stage bowel disease trial

Track these names every morning.

Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki

Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.

Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech

Immunic Appoints Jaa Roberson as Chief People Officer

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

What matters in this story

How each ticker is affected

Next reads from the same story arc

Gilead's pill succeeds in mid-stage bowel disease trial

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

What matters in this story

How each ticker is affected

Next reads from the same story arc

Gilead's pill succeeds in mid-stage bowel disease trial

Track these names every morning.

Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki

Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.

Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech

Immunic Appoints Jaa Roberson as Chief People Officer